home / stock / msb / msb news

MSB News and Press, Mesabi Trust

Stock Information
Company Name: Mesabi Trust
Stock Symbol: MSB
Market: NYSE
Website: mesabi-trust.com
Menu
MSB MSB Quote MSB Short MSB News MSB Articles MSB Message Board
Get MSB Alerts

News, Short Squeeze, Breakout and More Instantly...
MSB - Ryoncil® Profits Underpinning Substantial Growth Pipeline

NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended December 31, 2025 (H1 FY2026). FINANCIAL HIGHLIGHTS FO...
MSB - High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD

NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided data presented at the February 2026 Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTC...

MSB - Top small-cap materials stocks surging above 200-Day moving average

2026-02-11 11:11:41 ET More on small caps 2026: The Year Of The Small Cap? The Small Cap Rotation - Thoughts And How To Play It What Happens When Small Caps Win The Race To The 10th Trading Day? Top small-cap energy stocks surging above 200-Day moving average...

MSB - Ryoncil® Net Revenues Increase for the Quarter to US$30M

NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the second fiscal quarter ended December 31, 2025. “This quarter was high...
MSB - Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment

NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on use of Ryoncil ® (remestemcel-L-rknd) since commercially available in March 2025 for the approved label...

MSB - Mesabi Trust declares $0.26 dividend

2026-01-19 07:07:08 ET More on Mesabi Trust Mesabi Trust: Arbitration Upside Vs. Operational Reality Seeking Alpha’s Quant Rating on Mesabi Trust Dividend scorecard for Mesabi Trust Financial information for Mesabi Trus Read the full article ...

MSB - FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy

NEW YORK, Jan. 18, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided feedback received from the U.S. Food & Drug Administration (FDA) on potential filing of a Biologics License Applicatio...
MSB - SOLOWIN HOLDINGS acquires Canadian MSB license

2026-01-13 08:06:29 ET More on SOLOWIN HOLDINGS Seeking Alpha’s Quant Rating on SOLOWIN HOLDINGS Financial information for SOLOWIN HOLDINGS Read the full article on Seeking Alpha For further details see: SOLOWIN HOLDINGS acquires Canadian MSB license

MSB - Ryoncil® Sales Increase 60% in December Quarter to US$35.1M

NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue of US$35.1 million on Ryoncil ® (remestemcel-L-rknd) sales for the quarter ended December 31, 2025. 1...

MSB - Mesoblast Announces Changes to Board of Directors' Leadership Roles

NEW YORK, Jan. 01, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that as foreshadowed at the recent Annual General Meeting the Board will undertake a number of changes in line with the C...
Next 10